We aimed to investigate the cost-effectiveness of a 2000-gene-expression profiling (GEP) test to help identify the primary tumor site when clinicopathological diagnostic evaluation was inconclusive in patients with cancer of unknown primary (CUP). We built a decision-analytic-model to project the lifetime clinical and economic consequences of different clinical management strategies for CUP. The model was parameterized using follow-up data from the Manitoba Cancer Registry, cost data from Manitoba Health administrative databases and secondary sources. The 2000-GEP-based strategy compared to current clinical practice resulted in an incremental cost-effectiveness ratio (ICER) of $44,151 per quality-adjusted life years (QALY) gained. The total annual-budget impact was $36.2 million per year. A value-of-information analysis revealed that the expected value of perfect information about the test's clinical impact was $4.2 million per year. The 2000-GEP test should be considered for adoption in CUP. Field evaluations of the test are associated with a large societal benefit.
INTRODUCTION
The Canadian Cancer Society estimates that approximately 186,400 new cases of cancer will occur in Canada in 2014. 1 Approximately 4% are of metastatic cancer types not readily classified in the course of the initial diagnostic work up. 2 International and Canadian clinical guidelines recommend a further diagnostic work-up for these metastatic patients including immunohistochemical (IHC) analyses. 2 In the past decade, improvements in the number and accuracy of IHC stains have enabled pathologists and oncologists to make highly accurate tissue-of-origin diagnosis in many of these metastatic patients. 3, 4 However, the current success rate of the diagnostic work-up, even after exhaustive clinical and pathologic investigation, varies from 20 to 25%. 3, 4 Consequently, about 5000 new cancer cases are annually diagnosed with cancer of unknown primary (CUP) in Canada.
In the absence of a specific tumour diagnosis, there has been no consensus of defined treatment guidelines. Several broadspectrum empiric chemotherapeutic regimens (not specific for any particular type of cancer) based on combination regimens of platinum or taxane drugs have generally been used. 5, 6 However, patients have a poor prognosis with a median survival of 8-12 months from diagnosis and 1-year survival probabilities ranging from 15 to 35%. 3 The ability to identify a primary tumour site is an important goal in the clinical management of any patient with metastatic cancer. When tumour origins are known, patient outcomes including survival may improve because oncologists have better information on which to base treatment strategies. 7, 8 This allows patients to benefit from the increasing availability of specific chemotherapy regimens or therapies designed to target biologic characteristics of specific malignancies. 7, 8 Patients may also find value in knowing where their cancer originated from, independent of effects on prognosis and treatment.
Prediction of the likely primary tumour site by testing the biopsy specimen of the metastatic tumour is improving through the use of gene expression profiling techniques. 9, 10 To date, several gene expression-based tests have demonstrated the potential value of this approach in identifying the primary site. 4, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] One microarray-based test uses 2000-GEP to identify a tumour's primary site using formalin-fixed paraffin-embedded (FFPE) specimens (Tissue of Origin test, Response Genetics, Inc., Los Angeles, CA). 24 The test compares the RNA profile of a tumour FFPE specimen to established RNA profiles of 15 known tissues. Test results are presented as 15 similarity scores (SS) which are interpreted as probabilities, one for each of 15 different tissue types on the panel. The highest SS indicates the most likely tissue of origin. A maximum SS of 30 or less indicates indeterminate results which might occur if the specimen harbors less than 20% tumor content or if the tumour specimen is not represented by the 15 tissue types included in the test panel. 24 Specimen requirements include a minimum of 20% tumour content, a maximum of 20% necrosis and a minimum tumor area of 0.5 mm 2 . The 2000-GEP test was validated on 462 independent FFPE specimens derived from metastatic or poorly differentiated tumor specimens of known primary cancers and showed 89.3% sensitivity in identifying tumour's primary site. 24 Based on this analysis, the test was approved by the Food and Drug Administration in 2012 25 and has been available for clinical use in the United states. The 2000-GEP test results are intended for use in the context of the patient's clinicopathologic and radiologic history by a qualified oncologist and pathologist. [26] [27] [28] For instance, initial or additional clinical history, IHC analyses, and computed tomography (CT) scan images should be correlated and consistent with 2000-GEP tumour classification when suggesting a potential primary tumour site.
Although the test has been validated as a diagnostic tool, its impact on health and economic outcomes, if introduced into general practice for CUP patients, has not been determined. The 2000-GEP test has an official list price of $4400 CAD per patient. 29 As of September 2015, the test is not publically funded in any Canadian province. Current clinical management of CUP patients who are left without a primary tumour site diagnosis following clinical and pathological diagnostic workup undertaken according to current Canadian clinical practice has not been influenced by the availability of 2000-GEP testing. Generation of recommendations for Canadian clinical practice regarding the use of 2000-GEP test in CUP requires a comprehensive health economic evaluation of this approach in the Canadian setting. 30 In this project, we evaluated the incremental cost-effectiveness of using the 2000 GEP test to help identify the primary tumour when current clinical and pathological diagnostic evaluation fails to provide a diagnosis of primary tumour site for CUP patients.
METHODS

Model overview
We developed a decision analytic model 31 ( Figure 1 ) to estimate the lifetime clinical and economic consequences of different clinical management strategies for patients diagnosed with CUP following their clinical and pathological diagnostic workup undertaken according to current Canadian clinical practice. The model begins with a decision to use the 2000-GEP test or to continue with current clinical practice (CCP) (Figure 1a ). In the CCP strategy, we assumed that the primary tumour site stays undiagnosed and CUP patients are treated according to existing clinical practice (Figure 1b ). In the 2000-GEP-based strategy, we classified patients according to their occult primary tumour sites (Figure 1c ). For each occult primary tumour site, we assumed that the 2000-GEP test results would either be determinate (defined as classification of the tumour specimen to one of the 15 tissue types included in the test panel) or indeterminate (defined as highest SS is 30 or less) (Figure 1c ). Determinate 2000-GEP test results could either be correct or incorrect tumour classification (Figure 1c) . We assumed that determinate 2000-GEP test results would be used in the context of a patient's clinicopathologic and radiologic assessment (CRA) history by a qualified oncologist and pathologist when suggesting a primary tumour site (e.g., clinical history, immunohistochemistry analysis, and computer tomography scan images, etc). 26, 28, 32 When determinate 2000-GEP test classification (i.e., correct or incorrect) is found to be consistent with the CRA, we assumed that the test result will be considered to suggest a diagnosis of primary tumour which may be correct or incorrect and guide clinical management (Figure 1c ). When determinate 2000-GEP test classification is found to be inconsistent with CRA, we assumed that the test result will not be considered and primary tumour stays undiagnosed (Figure 1c ).
In the 2000-GEP-based strategy, other occult primary tumour sites represent tumour sites that are not covered by the 15 tissue types included in the test panel. For these occult primary tumour sites, we assumed that the 2000-GEP test results would either be indeterminate (defined as highest SS is 30 or less) or determinate but represent incorrect tumour classification (i.e., incorrect classification of the tumour specimen to one of the 15 tissue types included in the test panel).
CUP patients whose primary tumour stays undiagnosed in both strategies or those who have their primary tumour incorrectly diagnosed in the 2000-GEP-based strategy entered Markov model 'A' (Figure 1d ). CUP patients whose primary tumour is correctly diagnosed in the 2000-GEPbased strategy entered Markov model 'B' (Figure 1e ). Model 'A' differs from model 'B' in that it has an additional health state to account for the possibility that some CUP patients whose primary tumour site is undiagnosed or incorrectly diagnosed may have their true primary tumor site (i.e., diagnosis of latent primary tumour site) subsequently identified during the course of disease. 33 Model 'A' simulated monthly transitions among the following five distinct health states: (1) Initial diagnosis of metastasis of unknown primary (IDMUP); (2) diagnosis of latent primary (LP); (3) diagnosis of second primary (i.e., defined as a new primary malignancy) (SP); (4) palliative care (PC); and (5) death. Model 'B' simulated monthly transitions among the following four distinct health states: (1) Initial diagnosis of metastasis of known primary (IDMKP); (2) SP; (3) PC; and (4) death.
The analysis was conducted from the Canadian health care payer's perspective. We applied a discount rate of 5% per annum to costs, life years (LY) and quality adjusted life years (QALYs) following Canadian guidelines. 34 We used a lifetime horizon and half cycle correction. 35 24 and clinical verification of the test performance 26 (Table 1) . We estimated all other distributions in the decision tree and transition probabilities in the Markov models (Table 1 ) from the observed clinical management and survival outcomes in our study cohort. Full details are given in the Supplementary Appendix section B and Table A1 .
Costs and utilities
The cost of 2000-GEP test is estimated at $4400 CAD per patient. 29 We used the costs of hospital stays, medical claims and prescription claims to estimate the cost per unit time in each Markov state ( Table 2) . We derived utility estimates from secondary sources ( Table 3) . Full details are given in the Supplementary Appendix section C and D.
Sensitivity analyses
In deterministic sensitivity analysis we focused on three groups of parameters: (1) Parameters related to the accuracy of 2000-GEP testing (akin sensitivity of the test) across occult primary sites (i.e., defined as the probability of correct 2000-GEP test classification given that the test result is determinate); (2) Parameters related to incorrect diagnostic results following determinate 2000-GEP test results (i.e., when the primary tumour stays undiagnosed following correct 2000-GEP test classification or when the primary tumour is incorrectly diagnosed following incorrect 2000-GEP test classification); and (3) Parameters related to survival following correct primary tumour diagnosis (i.e., the transition probabilities from IDM to PC, SP, or dead states in the 2000-GEP Markov models following the chance nodes when the primary is correctly diagnosed). We included the latter group of parameters in our sensitivity analyses to test the possibility that CUP patients may not respond as well as their counterparts Patients entering Markov model "A" start the model and remain in the IDM state unless they develop LP or SP, start PC, or die. Patients who developed LP remain in the LP state or transition to SP, PC, or Dead states. Patients entering Markov model "B" start the model and remain in the IDM state unless they develop SP, start PC, or die. In both Markov models, patients who developed SP, remain in the SP state or make transition to PC or Dead states. Patients who started PC remain in the PC state or transition to Dead state. * A decision analytic models are mathematical model used to combine data from several clinical trials or administrative databases as well as expert clinical and scientific opinion in order to project the impact of medical interventions and estimate their incremental cost-effectiveness ratios (see Inadomi 31 for an introduction). A decision tree is a common type of decision analytic model and used to simulate a sequence of decisions and uncertain events that may occur in a simple notion of time (i.e., one direction left to right chronologically). There are no shortcuts in a standard tree structure for representing events that recur over time (see Inadomi 31 for introduction). † In the 2,000-GEP-based strategy, other occult primary tumour sites represent tumour sites that are not covered by the 15 tissue types included in the test panel. For these occult primary tumour sites, we assumed that the 2,000-GEP test results would either be indeterminate (defined as highest SS is 30 or less) or determinate but represent incorrect tumour classification (i.e., incorrect classification of the tumour specimen to one of the 15 tissue types included in the test panel) 26 . ‡ A Markov model is a common type of decision analytic model and used to project scenarios that involve transitions between various states of health over a short or long period of time. The model allows movement back and forth between health states to represent events that recur over time (see Sonnenberg and Beck 35 for an introduction). Abbreviations: CCP = Canadian clinical practice; GEP = Gene expression profiling; CRA = clinicopathologic and radiologic assessment; IDM = initial diagnosis of metastasis; LP = diagnosis of latent primary; SP = diagnosis of second primary; PC = palliative care.
2,000-GEP test versus CCP-guided clinical management. Cost-effectiveness of a gene expression profiling test MB Hannouf et al with metastatic of known primary cancers when their occult primary is identified and treated with current site-specific therapy. 56 We have separately performed additional deterministic sensitivity analyses on the cost of the test and probability of indeterminate test results across occult primary sites.
We conducted probabilistic sensitivity analysis using Monte Carlo simulation with 1000 iterations. Each iteration consisted of a random draw from an appropriate distribution for all model inputs (Tables 1, 2, 3) to produce a distribution of model outputs.
We also performed a value-of-information analysis 57 in which we estimated the expected monetary value of removing all statistical uncertainty about the clinical impact of the 2000-GEP test. 57, 58 In particular, we compared results with and without uncertainty related to accuracy of the 2000-GEP test, diagnostic results following determinate 2000-GEP test results, and survival following correct primary tumour diagnosis. Table A2 . Of those, 169 (15%) patients had their latent primary tumour site eventually detected during their life. During the same time period, there were 10 012 patients initially diagnosed with metastatic cancer of known primary. Of those, 202 (2%) patients had their cancer initially classified differently from their latent primary tumour identified later during life or at autopsy.
RESULTS
Base-case scenario
Our model predicted 1.13 LY, 0.63 QALY and $17,802 CAD for CUP (i.e., CCP-based strategy). By contrast, when the primary tumour is properly identified model outcomes ranged from 0.74 LY, 0.45 QALY, and $14,278 for metastatic cancer of hepatocellular primary tumour to 4.35 LY, 3.37 QALY, and $69,400 CAD for metastatic cancer of testicular germ cell primary tumour (Table 4) . Overall, the model predicted 1.42 LY, 0.87 QALY and 28,609 CAD for the 2000-GEP-based strategy. Abbreviations: CRA, Clinicopathologic and radiologic assessment; CUP, Cancer of unknown primary; MCR, Manitoba Cancer Registry; PSA, probabilistic sensitivity analysis; SS, Similarity score. a The Dirichlet distribution is a multinomial extension of the beta distribution. The Dirichlet distribution was used in PSA for the probability estimates of occult primary tumour sites to provide probabilistic probabilities over multiple branches (i.e., represent occult primary tumour sites) that appropriately represent uncertainty while satisfying the requirement that mutually exclusive event probabilities should sum to 1. 36 Base-case probability estimates of 100% were assumed to be 99% in PSA.
b The 2000-GEP test panel covers the following 15 tissue types: Hepatocellular, kidney, nonsmall cell lung, ovarian, pancreatic, prostate, and thyroid, melanoma, testicular germ cell, non-Hodgkins lymphoma, and sarcoma.
c The 2000-GEP test result is classified as indeterminate when the highest SS is 30 or less due to unique specimens harboring less than 20% tumor content, or actual tissue of origin for a given tumour specimen is not covered by the 15 tissue types included in the test panel. Cost received site-specific therapy based on a GEP diagnosis when compared to historical control patients. 8 Budget impact analysis We estimated the total expense of incorporating the 2000-GEP test into standard practice in Canada for CUP patients when current Normal distributions were used for cost parameters in the PSA to simulate uncertainty at the population level. 
Sensitivity analysis
The 2000-GEP-based strategy generated an ICER greater than $100,000 per QALY gained when the accuracy of the 2000-GEP test decreased by 50%, incorrect diagnostic results following 2000-GEP test classification increased by 20% and survival following correct primary diagnosis decreased by 30% (Figure 2) . In separate analyses, the cost of the test and probability of indeterminate test results across occult primary sites did not substantially influence our baseline outcomes. Other endocrine 0.800 51, 52 Weighted average utility of other primary tumour sites Weighted average was based on the observed distribution of latent primary tumour sites in our CUP cohort (Table 1) .
d Utility with CUP was derived after applying 13% reduction on the weighted average utility of metastasis of known primary. e For example, if a latent primary tumour is detected in the course of metastatic disease for a CUP patient and found to be breast tumour, then this patient will transition to the 'diagnosis of latent primary tumour' state and receive the utility of metastasis of breast cancer (which is equal to 0.715) while remaining in this health state unless this patient transition to other health states.
f For example, when a second primary tumour is detected in the course of metastatic disease of a CUP patient following Markov model 'A', this patient will transition from the 'initial diagnosis of metastasis of unknown primary' state (i.e., utility = 0.56) to the 'diagnosis of second primary tumour' state and receive 7% reduction in the utility of metastasis of unknown primary (i.e., 0.56 -(0.56*0.07) = 0.52) while remaining in this health state, unless this patient transitions to other health states. Full details on estimation procedures found in Supplementary Appendix Section D.
Using willingness to pay thresholds of $50,000 and $100,000 per QALY gained in probabilistic sensitivity analysis (Figure 3a) , we found that the 2000-GEP-based strategy was the preferred strategy in 78.2 and 99.6% of simulations, respectively (Figure 3b ).
Using our baseline ICER value of $44,151 per QALY gained as the willingness to pay, the opportunity cost associated with the choice of 2000-GEP-based strategy for guiding management of CUP resulted in a total expected value of partial perfect information (EVPPI) of $1266 per patient diagnosed with CUP of which $450 was due to uncertainty related to accuracy of the 2000-GEP test, $320 was due to uncertainty related to diagnostic results following determinate 2000-GEP test results, and $496 was due to uncertainty related to accuracy of survival following correct primary tumour diagnosis. The resulting total EVPPI for the entire CUP population that could be eligible for the 2000-GEP test in Canada was 3350 cases of CUP per year × $1266 per patient = $4.2 million CAD per year.
DISCUSSION
We developed a decision-analytic model to evaluate the cost effectiveness of using the 2000-GEP test to help identify primary tumours when current clinical and pathological diagnostic evaluation fails to provide a diagnosis of primary tumour site in CUP patients. In the base case, we estimated that the 2000-GEPbased strategy has an ICER of $37,774 per LY gained and $44,151 per QALY gained. These ICERs are below ICER estimates for a 21-GEP assay 59, 60 and cancer drugs that were recently recommended for adoption. 61, 62 The clinical benefit of 0.28 LY is comparable to several recently approved drugs for metastatic disease. [63] [64] [65] [66] The budget impact analysis shows that adoption of the 2000-GEP testing would lead to total incremental cost of $36.2 million per year.
Hospital laboratories in Canada receive fixed provincial funding to support all their operations and it is unlikely at this time that laboratories would reduce funding of other services to fund GEP tests conducted exclusively out of country. 67 Decisions to adopt these tests for funding are likely made at the provincial level but the processes and criteria used by the provincial ministries of health to evaluate and approve GEP tests are still evolving and yet to be defined. 67 However, the 2000-GEP test characteristics are comparable to those of the 21-GEP test for guiding adjuvant chemotherapy in early stage breast cancer which represents the first and only GEP test translated into clinical practice in Canada. Similar to the 2000-GEP test, the 21-GEP test was found promising as it may improve patient safety and likely pose low risk of harm, but had significant uncertainty associated with its clinical value. 59, 60 Budget impact analyses also demonstrated that adoption of the 21-GEP testing would lead to a total incremental cost of up to $23.5 million per year. 59, 60 The test was recently funded in several provinces within the context of field evaluations. Given the 2000-GEP test appears to be clinically promising and provides good value for money 34, 68 it could also be considered for special coverage such as coverage with evidence development. 57 A recent cost-effectiveness analysis of the 2000-GEP test was reported among patients with metastatic and poorly differentiated cancer of uncertain primaries (i.e., difficult-to-diagnose primary) for whom the majority had primary tumour site diagnoses reported by their physicians prior to 2000-GEP testing. 69 The test was found to have an ICER of $46,858 per QALY gained from a US third-party payer perspective. 69 These results in uncertain cancers cannot be extrapolated to the CUP setting because CUP patients are left without a primary tumour site diagnosis despite extensive clinical and pathological diagnostic evaluation. As a result management and clinical outcomes of CUP are different from those of cancer of uncertain primary.
Our sensitivity analyses demonstrated that the 2000-GEP test accuracy, diagnostic results following 2000-GEP test classification and survival response following correct primary diagnosis are important variables that influenced the ICER (Figure 2 ). For instance, when these three groups of parameters were negatively modified by approximately 35% (Figure 2d ) the ICER became well above ranges of a number of cancer treatments recently approved for funding in Canada 61, 62 and the 2000-GEP-based strategy may no longer deemed a cost effective use of resources. Our value-ofinformation analysis demonstrated that there is a significant societal benefit from future research that can better characterize these three groups of parameters. Taken together with the lack of future randomized trials of 2000-GEP testing in CUP population worldwide, 70 this suggests that clinical verifications and field evaluations of the test to establish its impact on Canadian management of CUP and resulting survival outcomes should be a priority. Markov models structure 'B' were only used in the 2000-GEP-based strategy when the primary tumour is correctly identified.
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Validation of any diagnostic test accuracy and clinical verification of resulting diagnostic decisions in a real-life CUP population remains a challenge since, by definition, the primary tumour site is not found except rarely in the clinical course of disease or more commonly at autopsy. 33, 71 For instance, validation analysis of the 2000-GEP test 24 used in our study was conducted in the United States in patients with known primary cancers. Genetic profiles of occult cancers giving rise to CUP may differ from known primary cancers. 71 A more direct study to evaluate the reliability of any GEP test and its impact on diagnostic decision making in CUP patients would be the correlation with an eventual primary tumour detected later during the course of the disease (latent primary) or at autopsy. This is possible because our analysis demonstrated that those cases are identifiable using cancer registries and future studies can further link such cases with their specimens from banks of tumour tissue samples to study any GEP test. This research approach is warranted to address concerns over potential incorrect 2000-GEP test classification and resulting diagnostic decisions; it would also be valuable for updating our model and verifying our results. Future clinical verification and field evaluations studies of GEP testing in CUP population should also explore any potential impact of † Incorrect diagnostic result was defined as occurring when either the primary stays undiagnosed following correct 2,000-GEP test classification of the tumour specimen or when the primary tumour is incorrectly diagnosed following incorrect 2,000-GEP test classification of the tumour specimen. ‡ Survival response following correct primary diagnosis was defined as the transition probabilities from IDM to PC, SP, or dead states in the 2,000-GEP Markov models following the chance nodes when the primary is correctly diagnosed. Survival response following correct diagnosis of hepatocellular, pancreas or non-small lung primary site was not included in sensitivity analyses as these potential primary sites were found to have worse QALYs compared to overall CUP group (Table 4) . Abbreviations: 2,000-GEP test = Tissue of Origin test; ICER = incremental cost effectiveness ratio; QALY = quality adjusted life year; CUP = cancer of unknown primary.
$50,000 < ICER $100,000 per QALY $100,000 < ICER $150,000 per QALY ICER > $150,000 per QALY intratumour heterogeneity on its results using multiple tumourbiopsy samples. 72 Our analysis has limitations. The estimated distribution of underlying primary tumours among CUP patients in our study does not necessarily reflect the distribution of underlying primary tumours among current CUP patients. Potential recent changes in the incidence of underlying different primary tumours in CUP population may affect the cost-effectiveness of the 2000-GEP testing. Outcomes and costs of therapies given in the 2002-2011 population do not also necessarily reflect the possible benefits and costs of newer site-directed therapies or dosing schedules used in very recent clinical practice so analysis with such data would be more applicable to the current practice landscape. It is unclear how the inclusion of these recent therapies may impact our results because patients with CUP represent a heterogeneous group and some new therapies might be marginally effective across certain tumour types. 70 Generalization of our study results to other health care systems may be limited by differences of clinical practice and different approaches to pricing and reimbursement.
CONCLUSION
We found that the 2000-GEP test provides good value for money in CUP patients for whom current clinical and pathological diagnostic evaluation does not provide a diagnosis of primary tumour site. However, clinical verifications and field evaluations of the test using multiple tumour-biopsy samples to establish its accuracy and impact on diagnostic decisions and survival in the CUP setting should be initiated in Canada to ensure its clinical utility.
